Prometheus Biosciences Profit Margin

The latest profit margin for RXDX is -3732.99% as of March 2023. That compares with -1749.08% in the prior-year period — down 113.4% year over year. That is below the Healthcare sector average of 14.34%. Investors often review this figure alongside Prometheus Biosciences's historical trend and sector peers before judging valuation or financial health.

Over the past year, RXDX's profit margin moved from -1749.08% to -3732.99% — a 113.4% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Prometheus Biosciences's valuation or profitability profile.

Against Healthcare companies, RXDX currently prints -3732.99% for profit margin, while the sector average sits near 14.34%. That is roughly 26123.3% below the sector mean. Large gaps often invite a closer look at Prometheus Biosciences's growth, margins, and balance sheet.

Profit Margin shows how effectively Prometheus Biosciences converts resources into returns. At -3732.99%, RXDX may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -1749.08% in the prior-year period — down 113.4% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting RXDX's profit margin (-3732.99%), review year-over-year change from -1749.08%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.